The pharmaceutical market and responsibility

A manufacturer wants sales. A patient wants relief from pain, anxiety or another difficulty; a clinician has to assess the possible benefit and harm for that patient. If these interests diverge, it does not help to declare every medicine dangerous or every prescription disinterested. What matters is evidence about the medicine, a clear reason for prescribing it, observation of the result and a chance to discuss whether the treatment should be reviewed.

The word drug in an English term for a pharmacy does not make every medicine a narcotic. Prescribed use, long-term use, physical adaptation, symptoms after stopping and a substance use disorder are different matters. The UK Royal College of Psychiatrists uses antidepressants as an example of why adaptation and withdrawal symptoms do not automatically establish addiction. That example does not erase risks of other medicines or justify stopping prescribed treatment on one's own.

According to a US Department of Justice release dated 24 November 2020, Purdue Pharma LP pleaded guilty to three federal felony counts in Newark, New Jersey. The company admitted that, from May 2007 through at least March 2017, it gave the Drug Enforcement Administration misleading information about efforts to prevent diversion of its opioids and about data relevant to manufacturing quotas. That is the procedural status of a named company and period, not a finding about every pharmaceutical manufacturer.

The same plea covered payments to two doctors through a speaker program from June 2009 to March 2017 intended to induce more prescriptions of Purdue opioid products. From April to December 2016, Purdue also paid the electronic health-records company Practice Fusion in exchange for recommending and arranging orders for the extended-release opioid products OxyContin, Butrans and Hysingla. The mechanism matters: a commercial incentive entered a route through which a clinical choice and an electronic prompt could appear neutral to a patient. These admitted actions do not mean that every person who received one of the medicines had a disorder or received no medical benefit.

The company's 2020 guilty plea was not the end of every legal process. A separate Justice Department release of 28 April 2026 reports that a federal court sentenced Purdue. An ordered amount and conditions for potential credits are not a report that the full sum has reached every harmed person. The date of the plea, the sentencing date and actual execution of the penalty must be kept apart.

The Justice Department also said that, apart from Purdue's criminal admissions, the matters resolved by civil settlements, including one involving the Sackler family, remained allegations with no civil liability determination in those matters. The family's settlement was not a personal criminal guilty plea. That distinction neither excuses harm nor prevents questions about redress; it avoids assigning an individual a court status that this document does not establish.

In Harrington v. Purdue Pharma L.P., decided on 27 June 2024, the US Supreme Court considered a specific provision of a Chapter 11 reorganisation plan. Its narrow holding was that such a plan could not extinguish claims against a nondebtor third party without the affected claimants' consent. The Court left other questions, including consensual releases, outside that holding. The document's syllabus is a headnote prepared by the Reporter of Decisions, not part of the Court's opinion.

This ruling did not undo Purdue's criminal plea or find members of the Sackler family guilty of a crime. The processes addressed different questions: what the company admitted, what criminal penalty was ordered and which claims a bankruptcy plan could discharge. Rights and remedies outside this US case depend on local law; this article cannot serve as individual legal advice.

The US CMS Open Payments programme publishes information reported by drug and device companies about payments to certain healthcare recipients. CMS says it does not decide whether a particular relationship is beneficial or a conflict of interest. A payment entry can prompt a sensible question about the source of a recommendation; it does not by itself prove a bribe, an improper prescription or lobbying. We did not inspect individual entries or draw a conclusion about a named clinician.

A lawful research payment, a disclosed speaking engagement, an admitted unlawful payment and political lobbying are different things. A claim that an organisation lobbied for a particular decision needs evidence of the action, recipient, period and applicable rules. The Purdue case documents specified violations; it does not establish a secret conspiracy by all manufacturers. A patient need not prove such a conspiracy to ask who funded a recommendation and what independent evidence of benefit and risk informed it.

On 8 January 2026, the UK medicines regulator MHRA announced stronger warnings for gabapentinoids, benzodiazepines and Z-drugs. It addressed risks of dependence, addiction, withdrawal and tolerance for those classes while also describing them as valuable treatments for many people. A warning calls for a discussion of risk and monitoring, not a diagnosis for everyone who receives a prescription. It does not cover every medicine or turn a patient's concern into a home stopping plan.

Questions for the prescriber can be straightforward: what is this medicine intended to do; how and when can benefit be assessed; which risks matter alongside other illnesses or medicines; who will review the result, and when; what alternatives exist; what will it cost; and whom should the person contact about unwanted effects or a possible change? If the decision is difficult to understand, ask for an explanation and an accessible second professional opinion. Do not change a dose, abruptly stop a prescribed medicine or attempt a home “detox” because of a publication or fear about the market.

For suspected poisoning by a medicine or another substance, the NHS calls for immediate medical help even before symptoms appear. For new sudden confusion, the NHS calls for immediate contact with an emergency medical service: sudden confusion alone is enough; do not wait for it to become “severe,” for another sign, for an admission or for the maker of a medicine to be identified. Outside the UK, contact the local emergency medical service. A family discussion or evidence gathering can wait.

Threats, coercion or violence require a separate safe contact with local protection or emergency services, before a joint conversation about medicines. The UK NHS page on domestic abuse describes this risk, but rules and access elsewhere must be checked locally. A child must not monitor medicines, translate a dangerous conversation, act as a messenger or provide adult care. If the child or another dependent person needs supervision, a capable adult or professional must actually provide it; a referral or answered phone call is not care in place.

A patient can ask specific questions. Family members can help formulate them when the person agrees and it is safe. Recording the medicine's name and purpose, observed changes, concerning symptoms and questions about reassessment can support a conversation with a clinician. It is not a way to diagnose or punish the patient. If a financial tie or promotion is in doubt, ask for an explanation, independent evidence and the local route for a complaint. Filing a complaint does not replace ongoing necessary care.

Check the actual route to help: who accepts people of the relevant age, in which language, at what cost, after what wait, with which data requirements, and what happens after the first contact. Consent, access to records, confidentiality and organisations' duties vary by place and circumstance; there is no absolute promise here. Care must not depend on faith, guilt, complete abstinence, public disclosure or winning a dispute with a company. Accountability in the market and the safety of a particular person can be sought at the same time.

• DOJ, Purdue guilty plea: press release, 24 November 2020, updated 5 February 2025; the company's criminal admissions and a civil-allegations caveat, not the full record of all cases.
• DOJ, Purdue sentencing: press release, 28 April 2026; the sentence and possible credits, without verification of payments to harmed people.
• US Supreme Court, Harrington v. Purdue Pharma L.P.: 27 June 2024; only targeted syllabus and holding passages on a nonconsensual nondebtor release were read. The full decision, later settlements and all consequences were not studied.
• CMS, Open Payments: official overview of a US disclosure database, page modified 30 June 2026; no individual entries were checked and disclosure alone is not a finding of wrongdoing.
• MHRA, warnings for three medicine classes: UK regulatory press release, 8 January 2026; neither a diagnosis nor a treatment-changing plan.
• Royal College of Psychiatrists, Antidepressants: UK patient information, March 2025, next review due March 2028; the adaptation example concerns the named class.
• NHS, Poisoning: UK guidance reviewed 12 June 2025; immediate medical help before symptoms.
• NHS, Sudden confusion: UK guidance reviewed 28 May 2024; immediate emergency contact for new sudden confusion.
• NHS, Domestic violence and abuse: UK guidance reviewed 23 June 2026; elsewhere, protection contacts and rules require local verification.

pharmaceutical market, responsibility, Purdue Pharma, opioids, prescriptions, financial ties, regulation, physical adaptation, addiction, safety, patient rights, access to care

Andrey Zarinsh — author and founder of United Wisdom. He explores inner transformation, the unity of traditions, intercultural dialogue, and contemporary spiritual discipline. Instagram: @andrey.zarinsh.

Maria Evilkut — co-author of United Wisdom. Alongside her research, she seeks to test these ideas in practice and observe how principles of unity and mutual understanding work in real life between people and cultures. Instagram: @ilkutki.

15 October 2026. English version.